JP2009504774A5 - - Google Patents

Download PDF

Info

Publication number
JP2009504774A5
JP2009504774A5 JP2008527161A JP2008527161A JP2009504774A5 JP 2009504774 A5 JP2009504774 A5 JP 2009504774A5 JP 2008527161 A JP2008527161 A JP 2008527161A JP 2008527161 A JP2008527161 A JP 2008527161A JP 2009504774 A5 JP2009504774 A5 JP 2009504774A5
Authority
JP
Japan
Prior art keywords
day
administered
use according
saha
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008527161A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009504774A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/032282 external-priority patent/WO2007022408A2/en
Publication of JP2009504774A publication Critical patent/JP2009504774A/ja
Publication of JP2009504774A5 publication Critical patent/JP2009504774A5/ja
Withdrawn legal-status Critical Current

Links

JP2008527161A 2005-08-18 2006-08-18 癌を治療するためにsaha及びターグレチンの併用方法 Withdrawn JP2009504774A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70959905P 2005-08-18 2005-08-18
US73375205P 2005-11-04 2005-11-04
PCT/US2006/032282 WO2007022408A2 (en) 2005-08-18 2006-08-18 Combination methods of saha and targretin for treating cancer

Publications (2)

Publication Number Publication Date
JP2009504774A JP2009504774A (ja) 2009-02-05
JP2009504774A5 true JP2009504774A5 (https=) 2009-09-10

Family

ID=37758430

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008527161A Withdrawn JP2009504774A (ja) 2005-08-18 2006-08-18 癌を治療するためにsaha及びターグレチンの併用方法

Country Status (6)

Country Link
US (1) US20090227674A1 (https=)
EP (1) EP1933825A2 (https=)
JP (1) JP2009504774A (https=)
AU (1) AU2006279400A1 (https=)
CA (1) CA2617623A1 (https=)
WO (1) WO2007022408A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101259120B (zh) 2002-03-04 2012-07-04 Hdac默克研究有限责任公司 辛二酰苯胺异羟肟酸或其可药用盐在制备诱导末期分化的药物的用途
TWI415603B (zh) 2005-05-20 2013-11-21 Merck Sharp & Dohme 1,8-辛二醯基苯胺羥胺酸(suberoylanilide hydroxamic acid)之調配物及其製配方法
CN101316583A (zh) 2005-09-30 2008-12-03 生命医药公司 用特异性rxr激动剂治疗癌症
US8536188B2 (en) * 2007-04-25 2013-09-17 Cyclacel Limited Dosing regimens for treatment of proliferative disorders comprising administration of sapacitabine
WO2013090616A1 (en) 2011-12-13 2013-06-20 Io Therapeutics, Inc. Autoimmune disorder treatment using rxr agonists
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
WO2015084905A1 (en) * 2013-12-03 2015-06-11 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and immunomodulatory drugs
ES2928499T3 (es) * 2014-05-21 2022-11-18 Aist Inhibición de la proliferación de células madre cancerosas
EP3280398B1 (en) * 2015-04-10 2026-02-25 Bioresponse LLC Self-emulsifying formulations of dim-related indoles
CN116077626A (zh) 2015-10-31 2023-05-09 Io治疗公司 使用rxr激动剂和甲状腺激素的组合治疗神经系统紊乱
US10835507B2 (en) * 2016-03-10 2020-11-17 Io Therapeutics, Inc. Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones
KR102605349B1 (ko) * 2016-03-10 2023-11-22 아이오 테라퓨틱스, 인크. Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료
WO2018089861A1 (en) * 2016-11-11 2018-05-17 The Regents Of The University Of California Methods and compositions for the treatment of cancer and metabolic diseases
CA3076373A1 (en) 2017-09-20 2019-03-28 Io Therapeutics, Inc. Treatment of disease with esters of selective rxr agonists
WO2020232399A1 (en) * 2019-05-16 2020-11-19 The Regents Of The University Of California Compositions comprising hdac inhibitors and retinoids
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
AU2022408160A1 (en) 2021-12-07 2024-06-06 Board Of Regents, The University Of Texas System Use of an rxr agonist and taxanes in treating her2+ cancers
CA3242047A1 (en) 2021-12-07 2023-06-15 Io Therapeutics, Inc. Use of an rxr agonist in treating drug resistant her2+ cancers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183388A1 (en) * 2001-02-01 2002-12-05 Gudas Lorraine J. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors

Similar Documents

Publication Publication Date Title
JP2009504774A5 (https=)
US8410092B2 (en) Two-component pharmaceutical composition for the treatment of pain
JP2014526503A5 (https=)
JP2006504795A5 (https=)
JP2010518122A5 (https=)
JP2009514874A5 (https=)
JP2015512406A5 (https=)
JP2005512995A5 (https=)
JP2009525343A5 (https=)
JPH01503539A (ja) 非鎮静抗ヒスタミン薬を含んでなる咳/風邪用混合物
JP2009522370A5 (https=)
JPWO2023027198A5 (https=)
JP2010521417A5 (https=)
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
Ventafridda et al. Non-steroidal antiinflammatory drugs as the first step in cancer pain therapy: double-blind, within-patient study comparing nine drugs
JP2024507810A5 (https=)
JP2019218379A5 (https=)
JP2008533127A5 (https=)
FI4426298T3 (fi) Uusia terapeuttisia yhdistelmiä, jotka käsittävät pirfenidonia ja pde4-estäjää, etenevien fibrosoivien interstitiaalisten keuhkosairauksien hoitamiseksi
JP2009517411A5 (https=)
JP2001515041A5 (https=)
JP2023549849A5 (https=)
JP2002534477A5 (https=)
CA2476939A1 (en) Pharmaceutical combinations of cox-2 inhibitors and opiates
JP2020533402A5 (https=)